IMVT-1402 is expected to enter phase 3 trials quickly following consultation with the FDA.

A prediction by 현대차증권 제약/바이오/의료기기 김현석. Statements are as reported by the cited publishers — not verified by DecisionGateway.

추후 FDA와의 협의를 통해 빠르게 임상 3상에 진입할 것으로 전망